Glucocorticoid Receptor News

«1 2...77 78 79 80 818283 84 85 86 87...1064 1065 »

||||||||||  fluocinolone acetonide / Generic mfg.
Enrollment open, Trial initiation date:  ILUV1MOIS2: Evaluation of Macular Edema After AcF Implant's Injection, 1 Month After the Last DXM Implant (clinicaltrials.gov) -  Feb 15, 2024
P=N/A, N=34, Recruiting,  Sponsor: Nantes University Hospital
Not yet recruiting --> Recruiting | Initiation date: Sep 2023 --> Jan 2024

||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
Enrollment closed, Combination therapy:  ITHACA: A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma (clinicaltrials.gov) -  Feb 14, 2024
P3, N=337, Active, not recruiting,  Sponsor: Sanofi
Not yet recruiting --> Recruiting | Initiation date: Sep 2023 --> Jan 2024 Recruiting --> Active, not recruiting

|||||||||| Blincyto (blinatumomab) / Astellas, Amgen
USE OF BLINATUMOMAB TO ACHIEVE REMISSION AND CONSOLIDATION WITH HAPLOIDENTICAL TRANSPLANT WITH CYCLOPHOSPHAMIDE FOR THE TREATMENT OF CHILDREN WITH REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2808;
As a strategy to achieve remission was used blinatumomab a dose 5 ?g/m2 for continous infusion of 48 hours during 7 days, increasing the dose to 15 ?g/m2 during 28 days, all patients received triple intrathecal therapy with methotrexate, arabinocide and hydrocortisone, two weeks after each cycle of blinatumomab, All patients received blinatumumab cycles hospitalized, during their stay the toxicity data related to blinatumumab was evaluated every day. The use of 2 cycles of blinatumumab is an efficient and safe strategy to achieve remission in children with relapsed/refractory ALL+19, consolidation with transplant is an efficient therapy, haploidentical transplant is an easily accessible and efficient strategy to consolidate to this group of patients in middle-income countries

|||||||||| Kymriah (tisagenlecleucel-T) / Novartis
TREATMENT WITH TISAGENLECLEUCEL OF RELAPSE REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2765;
In real world setting treatment with tisagenlecleucel had similar efficacy and safety as in clinical trials. Analysis of initial laboratory values could be used in real world setting to predict response to the treatment and development of complications, but further research is needed.

|||||||||| SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA WITH ASCT IN ONCOSALUD - AUNA BETWEEN 2015 AND 2021 (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2595;
The stage of MM, according to Salmon-Durie, was generally stage III (89%), and ISS was stage I in 35%, II in 29%, and III in 36% of the patients.First-line treatment was generally VRD (bortezomib, lenalidomide, and dexamethasone) in 34.1% of patients and VTD (bortezomib, thalidomide, and dexamethasone) in 22.2%. In our series, patients with MM who received ASCT had a better survival rate than those who did not receive it; these findings are similar to those reported in other series.

|||||||||| Enbrel (etanercept) / Pfizer, Amgen
SEVERE POLYAUTOIMMUNITY AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: POTENTIAL ROLE OF THE GENETIC BACKGROUND AND CHIMERISM LOSS (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2537;
Moreover, although genetic testing is currently ongoing, it highlights the need for searching for underlying causes responsible both for the early development of malignancies and immune dysregulation in this category of patients, as the knowledge in the field of inborn errors of immunity with immune dysregulation is rapidly expanding. Finally, the chimerism reduction observed in this patient opens interesting physiopathological and clinical perspectives.

|||||||||| Jakafi (ruxolitinib) / Novartis, Incyte
SALVAGE THERAPY WITH NINTEDANIB AND LOW-DOSE RUXOLITINIB LEADS TO SIGNIFICANT IMPROVEMENT IN PATIENTS WITH BRONCHIOLITIS OBLITERANS SYNDROME WHO FAILED CALCINEURIN AND GLUCOCORTICOIDS AFTER ALLOGENEIC TRANSPLANTATION (Hall 3 North) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2510;
The RN protocol, featuring low-dose Ruxolitinib and Nintedanib, has demonstrated positive clinical responses in BOS. These findings provide support for the prospective evaluation of the RN protocol in a phase II study in the near future.

|||||||||| Yescarta (axicabtagene ciloleucel) / Gilead
SAFETY AND EFFICACY OF BENDAMUSTINE VERSUS FLUDARABINE-CYCLOPHOSPHAMIDE LYMPHODEPLETION PRIOR TO CAR-T CELL THERAPY WITH AXICABTAGENE CILOLEUCEL FOR NON-HODGKIN LYMPHOMA: A SINGLE-INSTITUTION STUDY (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2493;
In this retrospective study comparing Benda to FluCy lymphodepletion prior to axi-cel, Benda yielded similar efficacy with significantly less early hematologic toxicity. Although CRS and ICANS rates were similar, this is confounded by increased utilization of prophylaxis in the Benda group.

|||||||||| Yescarta (axicabtagene ciloleucel) / Gilead
SAFETY AND EFFICACY OF BENDAMUSTINE VERSUS FLUDARABINE-CYCLOPHOSPHAMIDE LYMPHODEPLETION PRIOR TO CAR-T CELL THERAPY WITH AXICABTAGENE CILOLEUCEL FOR NON-HODGKIN LYMPHOMA: A SINGLE-INSTITUTION STUDY (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2492;
In this retrospective study comparing Benda to FluCy lymphodepletion prior to axi-cel, Benda yielded similar efficacy with significantly less early hematologic toxicity. Although CRS and ICANS rates were similar, this is confounded by increased utilization of prophylaxis in the Benda group.

|||||||||| Darzalex (daratumumab) / J&J
SAFETY AND EARLY EFFICACY OF TANDEM AUTOLOGOUS STEM-CELL TRANSPLANTATION AFTER DARATUMUMAB VTD INDUCTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2488;
Transplantation outcomes were favorable, with both limited hematological and non-hematological toxicities. Although longer follow-up is required to further elucidate its benefit, tandem ASCT proved effective to increasing the depth of response in HR-MM

|||||||||| Darzalex (daratumumab) / J&J
SAFETY AND EARLY EFFICACY OF TANDEM AUTOLOGOUS STEM-CELL TRANSPLANTATION AFTER DARATUMUMAB VTD INDUCTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2487;
Transplantation outcomes were favorable, with both limited hematological and non-hematological toxicities. Although longer follow-up is required to further elucidate its benefit, tandem ASCT proved effective to increasing the depth of response in HR-MM

|||||||||| Jakafi (ruxolitinib) / Novartis, Incyte
RUXOLITINIB AS SECOND-LINE TREATMENT FOR BOS AFTER HEMATOPOIETIC CELL TRANSPLANTATION (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2478;
We found ruxolitinib was effective and safe as a second-line option for BOS post-HCT. The efficacy could be improved if used ruxolitinib earlier after diagnosis or when the lung symptom score is low.

|||||||||| Jakafi (ruxolitinib) / Novartis, Incyte
RUXOLITINIB AS SECOND-LINE TREATMENT FOR BOS AFTER HEMATOPOIETIC CELL TRANSPLANTATION (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2477;
We found ruxolitinib was effective and safe as a second-line option for BOS post-HCT. The efficacy could be improved if used ruxolitinib earlier after diagnosis or when the lung symptom score is low.

|||||||||| REAL-WORLD OUTCOMES OF UPFRONT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH DEL (17P) (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2403;
The co-occurrence of del(17p) and t(4;14) was associated with particularly poor outcomes. These high-risk patients may benefit from the incorporation of newer treatment modalities including bispecific antibodies and chimeric antigen receptor T (CAR-T) cells early in the course of treatment.

|||||||||| REAL-WORLD OUTCOMES OF UPFRONT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH DEL (17P) (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2402;
The co-occurrence of del(17p) and t(4;14) was associated with particularly poor outcomes. These high-risk patients may benefit from the incorporation of newer treatment modalities including bispecific antibodies and chimeric antigen receptor T (CAR-T) cells early in the course of treatment.

|||||||||| Cytovene (ganciclovir) / Roche
POSTTRANSPLANT COMPLICATIONS IN A CASE OF LATE-ONSET FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS TYPE 2 (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2285;
These high-risk patients may benefit from the incorporation of newer treatment modalities including bispecific antibodies and chimeric antigen receptor T (CAR-T) cells early in the course of treatment. Immunosuppression was switched to dexamethasone and cyclosporine in accordance with the HLH-2004 protocol...During that time, she suffered from a CMV infection for which she was treated with ganciclovir...Myeloablative conditioning with Busulfan (AUC 85-95), Fludarabine (160 mg/m

|||||||||| Carvykti (ciltacabtagene autoleucel) / J&J
PATIENT-REPORTED OUTCOMES CARTITUDE-4 STUDY (PHASE 3) OF CILTACABTAGENE AUTOLEUCEL VS STANDARD OF CARE IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA AFTER 1 (Hall 5) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2217;
P3
Immunosuppression was switched to dexamethasone and cyclosporine in accordance with the HLH-2004 protocol...During that time, she suffered from a CMV infection for which she was treated with ganciclovir...Myeloablative conditioning with Busulfan (AUC 85-95), Fludarabine (160 mg/m Clinical Trial Registry: NCT04181827 Background: The phase 3 CARTITUDE-4 trial (NCT04181827) in patients with multiple myeloma (MM) after 1

|||||||||| PALLIATIVE CARE IN CAR T THERAPY (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2204;
This case served as an eye-opener for our team, given the patient's prior active, independent, and well-functioning state, reminding us of the potential life-threatening side effects CAR-T can cause. It highlighted the importance of palliative care involvement in these cases where it is important for parallel planning from the outset - hoping for the best but also preparing for the worst.

|||||||||| bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
OUTCOMES IN AFRICAN-AMERICAN (AA) AND WHITE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA RECEIVING RVD-ALONE VS RVD+ASCT IN DETERMINATION: EFFICACY, SAFETY, AND SECOND PRIMARY MALIGNANCIES (SPMS) (Hall 5) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2164;
P3
DETERMINATION data suggest similar PFS/OS with RVd-alone and RVd+ASCT in AA patients (as with RVd+ASCT in AA/White patients overall) but indicate possible meaningful PFS benefit from RVd-alone upon exploratory analyses in certain subgroups. Overall grade ?3 hematologic toxicity rates were similar in AA/White patients within each arm despite Duffy-null prevalence of 65% in AA patients and associated lower baseline neutrophil counts, but grade ?3 neuropathy rates were higher in AA patients (consistent with GRIFFIN; Nooka, Blood Cancer J 2022), which taken together may reflect differential effects on the inflammasome and differences in myeloma pathobiology

|||||||||| varnimcabtagene autoleucel (ARI-0001) / August Pi i Sunyer Biomedical Research Institute, Actemra IV (tocilizumab) / Roche, JW Pharma
NURSING CARE PLAN IN EARLY HOME CARE AFTER CAR-T THERAPY: CASE REPORT (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2101;
The program favours patient-caregiver relationship, the acquisition of knowledge, avoids isolation from the nuclear family and reduces the number of hospitalization days. Highlighting the ability and requirements of the HCU to adopt therapeutic and logistic strategies that ensure proper home-care management, foundations for a future program of comprehensive home management are being set.

|||||||||| Darzalex (daratumumab) / J&J
MOBILIZATION AND HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA WITH DARATUMUMAB-BASED INDUCTION TREATMENS (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2010;
Background: Standard first-line treatment for patients with newly diagnosed Multiple Myeloma (MM) transplantation candidates includes combinations with Bortezomib and Dexamethasone, Thalidomide, Lenalidomide, Cyclophosphamide or Doxorubicin. In our experience, inclusion of Daratumumab in the induction regimen for transplant-eligible patients with MM resulted in a reduction in stem cell mobilization and stem cell yield, although our number of cases is still low to drawing conclusions.Treatment with quadruplets with Daratumumab in first line does not preclude successful mobilization or subsequent HSCT, although an increased use of Plerixafor and novel strategies such as early mobilization may be required, given the speed and depth of responses that are achieved with this type of regimen.

|||||||||| IMPROVED SURVIVAL OF MULTIPLE MYELOMA PATIENTS IN RELAPSE AFTER AUTOLOGOUS STEM CELL FOR THOSE WHO PREVIOUSLY ACHIEVED COMPLETE REMISSION AFTER TRANSPLANT (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1815;
Achieving CR or better post-ASCT is associated with improved PFS2 and improved OS from the time of post-transplant relapse indicating that these patients have a more sensitive disease that would respond better to subsequent treatments. These data are specifically significant with the currently expanding treatment landscape for patients with multiple myeloma and suggest an important endpoint in trials as well as an additional factor to take into consideration when deciding on treatment sequencing in the future.

|||||||||| Darzalex (daratumumab) / J&J
IMPACT OF DARA-VTD INDUCTION THERAPY ON HEMATOPOIETIC STEM CELL COLLECTION AND ENGRAFTMENT IN MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR ASCT: RESULTS OF THE REAL-LIFE PRIMULA STUDY (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1760;
These data are specifically significant with the currently expanding treatment landscape for patients with multiple myeloma and suggest an important endpoint in trials as well as an additional factor to take into consideration when deciding on treatment sequencing in the future. Clinical Trial Registry: ID RSO 249 Background: Induction therapy with daratumumab/bortezomib/thalidomide/dexamethasone (D-VTd) is currently a standard of care in transplant eligible patients with newly diagnosed Multiple Myeloma (MM)...Patients underwent ASCT after conditioning with melphalan (100-200mg/m

|||||||||| Darzalex (daratumumab) / J&J
IMPACT OF DARA-VTD INDUCTION THERAPY ON HEMATOPOIETIC STEM CELL COLLECTION AND ENGRAFTMENT IN MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR ASCT: RESULTS OF THE REAL-LIFE PRIMULA STUDY (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1759;
Clinical Trial Registry: ID RSO 249 Background: Induction therapy with daratumumab/bortezomib/thalidomide/dexamethasone (D-VTd) is currently a standard of care in transplant eligible patients with newly diagnosed Multiple Myeloma (MM)...Patients underwent ASCT after conditioning with melphalan (100-200mg/m Clinical Trial Registry: ID RSO 249 Background: Induction therapy with daratumumab/bortezomib/thalidomide/dexamethasone (D-VTd) is currently a standard of care in transplant eligible patients with newly diagnosed Multiple Myeloma (MM)...Patients underwent ASCT after conditioning with melphalan (100-200mg/m

|||||||||| Darzalex (daratumumab) / J&J
IMPACT OF DARATUMUMAB, BORTEZOMIB, THALIDOMIDE DEXAMETHASONE INDUCTION THERAPY ON STEM CELL MOBILIZATION: A REAL WORLD EXPERIENCE (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1758;
Our retrospective analysis showed a low rate of mobilization failures after dara vtd induction. We furthermore found no difference on CD 34 total yeald after 3 or 4 cicles of dara VTD and when mobilization was performed after more or less of 21 days ater last daratumumab administration.Prospective trials are needed to confirm feasibility of chemo free G CSF stem cell mobilization after Daratumomab VTD induction.

|||||||||| dexamethasone / Generic mfg., mycophenolate mofetil / Generic mfg., cyclosporine / Generic mfg.
HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN A LOW RESOURCE COUNTRY NIGERIA. A 10 YEARS REPORT FROM A SINGLE CENTER (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1616;
Haplo HSCT may become a possible source of donors and the use of single peripheral non cryopreserved stem cell dose in place of double tandem has made it possible for many developing countries to perform autologous HSCT for Multiple Myeloma patients. Overall survival is comparable to data from other centers.

|||||||||| dexamethasone / Generic mfg., mycophenolate mofetil / Generic mfg., cyclosporine / Generic mfg.
HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN A LOW RESOURCE COUNTRY NIGERIA. A 10 YEARS REPORT FROM A SINGLE CENTER (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1615;
Haplo HSCT may become a possible source of donors and the use of single peripheral non cryopreserved stem cell dose in place of double tandem has made it possible for many developing countries to perform autologous HSCT for Multiple Myeloma patients. Overall survival is comparable to data from other centers.

|||||||||| melphalan / Generic mfg., busulfan / Generic mfg.
FOLLOW-UP OF TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA RECEIVED BUSULFAN-BASED CONDITIONING VERSUS HIGH-DOSE MELPHALAN (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1562;
The conditioning regimens were as follows, busulfan-based regimen was composed of busulfan 3.2 mg/kg from days -7 to days -5, etoposide 200 mg/m2 from days -5 to days -4, cyclophosphamide 50 mg/m2 from days -3 to days -2 and HEMEL conditioning regimen consisted of melphalan from 140 mg/m2 to 200 mg/m2... Our results of the follow-up study showed that a busulfan-based conditioning regimen of BuCyE could be expected to prolong PFS and survival through secondary treatment compared to the high-dose melphalan conditioning regimen.

|||||||||| Yescarta (axicabtagene ciloleucel) / Gilead
FINAL RESULTS OF PROSPECTIVE CLINICAL TRIAL EVALUATING OUTPATIENT ADMINISTRATION OF AXICABTAGENE CILOLEUCEL IN HIGH-GRADE B CELL LYMPHOMA (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1542;
P=N/A
This prospective feasibility trial confirmed that axi-cel can be safely administered in the outpatient settings with prophylactic steroids and remote monitoring with wearable devices without compromising safety or efficacy of CAR T therapy. Longer follow-up data will be presented at the meeting.

|||||||||| Yescarta (axicabtagene ciloleucel) / Gilead
FINAL RESULTS OF PROSPECTIVE CLINICAL TRIAL EVALUATING OUTPATIENT ADMINISTRATION OF AXICABTAGENE CILOLEUCEL IN HIGH-GRADE B CELL LYMPHOMA (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1541;
P=N/A
This prospective feasibility trial confirmed that axi-cel can be safely administered in the outpatient settings with prophylactic steroids and remote monitoring with wearable devices without compromising safety or efficacy of CAR T therapy. Longer follow-up data will be presented at the meeting.

|||||||||| Cytovene (ganciclovir) / Roche, Vistide (cidofovir) / Gilead
ETIOLOGY OF DIARRHEA IN PATIENTS UNDERGOING COLONOSCOPIC BIOPSIES POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FOR SUSPECTED ACUTE GUT GRAFT VERSUS HOST DISEASE (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1462;
The initial treatment of histologically proven lower-gut aGVHD was 1-2 mg/kg methylprednisolone with oral budesonide. If biopsy showed concomitant CMV inclusion bodies (proven CMV colitis) or PCR copies >103IU/ml (possible CMV colitis), then ganciclovir 5mg/kg BD was started at physician

|||||||||| Cytovene (ganciclovir) / Roche, Vistide (cidofovir) / Gilead
ETIOLOGY OF DIARRHEA IN PATIENTS UNDERGOING COLONOSCOPIC BIOPSIES POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FOR SUSPECTED ACUTE GUT GRAFT VERSUS HOST DISEASE (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1461;
The initial treatment of histologically proven lower-gut aGVHD was 1-2 mg/kg methylprednisolone with oral budesonide. If biopsy showed concomitant CMV inclusion bodies (proven CMV colitis) or PCR copies >103IU/ml (possible CMV colitis), then ganciclovir 5mg/kg BD was started at physician

|||||||||| Darzalex (daratumumab) / J&J
ENGRAFTMENT SYNDROME IN PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: A SINGLE-CENTER DATA ANALYSIS OF CLINICAL FEATURES AND RISK FACTORS (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1436;
The management of ES depending on the patient's symptoms, either prednisone at 15-20 mg/day or dexamethasone at 5-10 mg qd or qod was prescribed...In the single-factor analysis?no difference was found in age, gender diagnostic subtypes, prior cyclophosphamide (CTX) application, disease status during collection and transplantation and treatment lines.And Application of daratumumab and carfilzomib, mobilization with and higher CD34 reinfusion count were not associated with higher risk of ES... From this data, the combination of bortezomib in the preconditioning regimen were identified as independent high-risk factors for ES.

|||||||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica, netupitant (Ro 67-3189) / Helsinn, Otsuka
EFFICACY AND SAFETY OF NETUPITANT/PALONOSETRON COMBINATION (NEPA) AND LOW DOSE OF DEXAMETHASONE IN PREVENTING NAUSEA AND VOMITING IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1406;
From this data, the combination of bortezomib in the preconditioning regimen were identified as independent high-risk factors for ES. NEPA and low dose of dexamethasone, administered every other day, show to be very effective in preventing CINV in patients undergoing alloSCT with a good tolerability profile

|||||||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica, netupitant (Ro 67-3189) / Helsinn, Otsuka
EFFICACY AND SAFETY OF NETUPITANT/PALONOSETRON COMBINATION (NEPA) AND LOW DOSE OF DEXAMETHASONE IN PREVENTING NAUSEA AND VOMITING IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1405;
NEPA and low dose of dexamethasone, administered every other day, show to be very effective in preventing CINV in patients undergoing alloSCT with a good tolerability profile NEPA and low dose of dexamethasone, administered every other day, show to be very effective in preventing CINV in patients undergoing alloSCT with a good tolerability profile

|||||||||| Carvykti (ciltacabtagene autoleucel) / J&J
EFFICACY AND SAFETY IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA AND 1 (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1399;
P3
Clinical Trial Registry: NCT04181827 Background: CARTITUDE-4 (NCT04181827) is a randomized, phase 3 trial comparing ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, with standard of care (SOC; pomalidomide, bortezomib, and dexamethasone [PVd] or daratumumab, pomalidomide, and dexamethasone [DPd]) in patients with lenalidomide (len)-refractory multiple myeloma (MM). This analysis shows potent effects of cilta-cel in patients with len-refractory MM after 1

|||||||||| Carvykti (ciltacabtagene autoleucel) / J&J
EFFICACY AND SAFETY IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA AND 1 (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1398;
P3
Clinical Trial Registry: NCT04181827 Background: CARTITUDE-4 (NCT04181827) is a randomized, phase 3 trial comparing ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, with standard of care (SOC; pomalidomide, bortezomib, and dexamethasone [PVd] or daratumumab, pomalidomide, and dexamethasone [DPd]) in patients with lenalidomide (len)-refractory multiple myeloma (MM). This analysis shows potent effects of cilta-cel in patients with len-refractory MM after 1

|||||||||| cyclosporine / Generic mfg.
EARLY LOW DOSE CYCLOSPORINE AND MYCOPHENOLATE REDUCE THE RISK OF CYTOKINE RELEASE SYNDROME AFTER HLA-HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL TRANSPLANTATION WITH PTCY BASED GVHD PROPHYLAXIS (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1360;
Main limitation of the study is that is is retrospective and based on a chart review. Prospective randomized comparison with standard ptCy/CsA/MMF schedule is needed to confirm these results.

|||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
EARLIER INTRATHECAL DEXAMETHASONE EFFECTIVELY ALLEVIATE IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1353;
For patients with CRS more than grade 2 combined with ICANS, they received intrathecal dexamethasone, intravenous steroid and tocilizumab. Intrathecal dexamethasone can effectively treat ICANS with or without CRS and significantly reduce dosage and duration of systemic corticosteroids, thereby improving the remission rates, RFS and PFS of these patients

|||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Darzalex (daratumumab) / J&J
DELAYED ICANS IN POST BCMA CAR-T CELL THERAPY CHALLENGES (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1284;
Late complications like Movement and Neurocognitive Toxicities (MNT) and Delayed ICANS are part of this but also the cytopenia and infection is another. High index of suspicion and close follow up is important for better support and adequate management for such patients

|||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
CYTOKINE RELEASE SYNDROME AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION AND ITS IMPACT ON OVERALL SURVIVAL (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1266;
[ps1] The effectiveness of tocilizumab or dexamethasone in addressing haplo-CRS remains uncertain, lacking definitive support from randomized trials. Exploring interventions to mitigate haplo-CRS, such as the early initiation of CNI and MMF (adopted at our center as of February 2023), emerges as a potential avenue for improving outcomes to mitigate morbidity from more severe forms of CRS.

|||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
CYTOKINE RELEASE SYNDROME AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION AND ITS IMPACT ON OVERALL SURVIVAL (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1265;
[ps1] The effectiveness of tocilizumab or dexamethasone in addressing haplo-CRS remains uncertain, lacking definitive support from randomized trials. Exploring interventions to mitigate haplo-CRS, such as the early initiation of CNI and MMF (adopted at our center as of February 2023), emerges as a potential avenue for improving outcomes to mitigate morbidity from more severe forms of CRS.

|||||||||| dexamethasone / Generic mfg.
CORTICOSTEROIDS IMPAIR HEMATOPOIETIC MICROENVIRONMENT VIA INDUCING SENESCENCE OF THE MESENCHYMAL STROMAL NICHE (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1240;
This may underlie the diminished capacity of MSCs to support hematopoiesis observed in patients with steroid-resistant or steroid-refractory GVHD patients. And the compromised osteogenic ability of BM-MSCs following steroid treatment may lead to osteoporosis.

|||||||||| dexamethasone / Generic mfg.
CORTICOSTEROIDS IMPAIR HEMATOPOIETIC MICROENVIRONMENT VIA INDUCING SENESCENCE OF THE MESENCHYMAL STROMAL NICHE (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1239;
This may underlie the diminished capacity of MSCs to support hematopoiesis observed in patients with steroid-resistant or steroid-refractory GVHD patients. And the compromised osteogenic ability of BM-MSCs following steroid treatment may lead to osteoporosis.

|||||||||| COMPARISON OF MOBILIZATION REGIMENS USED IN LYMPHOMA AND FACTORS THAT INFLUENCE PERIPHERAL BLOOD STEM CELL MOBILIZATION (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1195;
GDP and cytarabine-based regimen have better mobilization success compared to ifosfamide-based regimen or GCSF (with or without plerixafor) in lymphoma patients. Ifosfamide-based mobilization regimens are best avoided in patients who receive radiation to mediastinum, spine, or pelvis due to high failure rates.

|||||||||| COMPARISON OF MOBILIZATION REGIMENS USED IN LYMPHOMA AND FACTORS THAT INFLUENCE PERIPHERAL BLOOD STEM CELL MOBILIZATION (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1194;
GDP and cytarabine-based regimen have better mobilization success compared to ifosfamide-based regimen or GCSF (with or without plerixafor) in lymphoma patients. Ifosfamide-based mobilization regimens are best avoided in patients who receive radiation to mediastinum, spine, or pelvis due to high failure rates.

|||||||||| CHALLENGES IN CHIMERIC ANTIGEN RECEPTOR-T CELL PRODUCT ADMINISTRATION IN A HIGH TUMOR-BURDEN ELDERLY PATIENT WITH MANTLE-CELL LYMPHOMA (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1108;
In this older patient, it could be difficult differentiate neurological age-related symptoms from ICANS manifestations. Imaging, associated with monitoring of peripheral CAR-T cells, cytokine levels and other biomarkers, such as Nfl, could be helpful.

|||||||||| Ovastat (treosulfan) / Medac, Medexus
CENTRAL NERVOUS SYSTEM TOXICITY WITH EXCLUSIVE INVOLVEMENT OF THE BRAIN WHITE MATTER LIKELY RELATED TO TOXIC/IMMUNOLOGIC CAUSES. A PRESENTATION OF 4 SIMILAR CASES (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1103;
The ones we described are not dependent on metabolic or infectious complications, neither related to calcineurin inhibitors. Fludarabine is the only drug shared by all pts, instead ATG was used in 3 pts (included the only pts who had a positive outcome).

|||||||||| Kymriah (tisagenlecleucel-T) / Novartis, Actemra IV (tocilizumab) / Roche, JW Pharma, Yescarta (axicabtagene ciloleucel) / Gilead
ACUTE INFECTION AND BASELINE C-REACTIVE PROTEIN (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_863;
This study provides evidence for an unexpected association between this ACPI28 and risk of early lymphoma progression. We speculate that this could be due to poor CAR-T expansion due to adverse cytokine profile precipitated by the immune response to severe infection.

|||||||||| Kymriah (tisagenlecleucel-T) / Novartis, Actemra IV (tocilizumab) / Roche, JW Pharma, Yescarta (axicabtagene ciloleucel) / Gilead
ACUTE INFECTION AND BASELINE C-REACTIVE PROTEIN (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_862;
This study provides evidence for an unexpected association between this ACPI28 and risk of early lymphoma progression. We speculate that this could be due to poor CAR-T expansion due to adverse cytokine profile precipitated by the immune response to severe infection.



	Diseases Companies Products Productz Mechanisms of Action Sites